Celebrating twenty years2006 — 2026

Twenty years
in the cold chain.

Empowering Cold Chainge

Independent pharmaceutical cold-chain packaging and shipping-lane qualification and strategy for biotech and pharma QA and supply-chain teams.

Tell us where the cold chain is uncertain and we will tell you what it would take to make it defensible: strategy, evidence and the answer at the filing.

Carli Derifield, Founder of Cold Chain Consult
Carli DerifieldFounder & SME Consultant
Newport Beach, CaliforniaFounded 2006Inc. 5000 No. 2950#20YearsInTheCold
5M+
Shipments guided
0
Temperature failures
30+
Organizations guided
7
Continents
20
Years in the cold
Why we do it

There is a person at the end of every shipment, waiting for something they cannot live without.Twenty years on, that is still the only reason any of this matters.

— Carli Derifield, Founder

01What we do

Every link in the cold chain.

01

Strategy & Advisory

Transportation validation strategy, best-practice roadmaps, embedded SME support.

02

Regulatory & BLA

BLA transportation content, information-request responses, CAPA and audit resolution.

03

Lane Qualification

Lane and mode qualification, route and SLA validation, PQ ship studies.

04

Lane Mapping & ATP

Lane mapping studies, ambient temperature profiles, simulation and forecasting.

05

Qualification Testing

Thermal DQ/OQ, distribution hazard testing, shipper and facility mapping.

06

Quality Risk Review

Qualification package review, ICH Q9(R1) risk assessment, gap closure.

07

Network Optimization

Site, lane and packaging audits, SKU rationalization, supplier RFI and RFP.

08

Coaching & Augmentation

Training your team, temporary cold chain capacity, an expert on call.

02How we engage

Strategy, Execution and Defense. One owner.

1

Strategy

Defines what must be proven, for which lanes and configurations, and to what acceptance criteria. Ends with an approvable strategy and a remediation plan.

2

Execution

Produces the evidence against that definition: master plan, thermal assessments, simulation, qualification protocols and reports.

3

Defense

Carries the package into the submission and stands behind it: summary report, CTD content, agency responses and inspection readiness.

Every handoff between these is where misinterpretation enters, and that risk lands on the sponsor, at the filing. We will take one phase or all three, but we will always tell you which structure protects you.

03Where we work

Every thermal system, ambient to cryogenic.

Controlled Ambient
+15 to +25 °C

CRT product, apheresis collection and ancillary material. Short, time-critical lanes where dwell and tarmac exposure do the damage.

Refrigerated
+2 to 8 °C

Biologics, vaccines, LNP drug product, drug substance and critical raw materials maintained at +2 to +8 °C from parcel to pallet. Frozen components at −20 °C and below travel separately on dry ice, with sublimation and dangerous-goods controls.

Cryogenic
Below −150 °C

Cell and gene therapy finished product in LN2, with depot storage, chain of identity and lot-to-patient custody carried end to end.

Every thermal system, parcel to pallet and truck.

07Selected work · anonymized

What the work looks like when it is done.

01Phase I biologic · three EU clinical sites

The carrier had data. Nobody had qualified the lane.

Problem

A first-in-human program was shipping to three investigator sites on a carrier’s generic summer pack-out. The sponsor could produce transit temperatures but not a defensible qualification for the payload, the duration or the handoffs, and a sponsor audit was six weeks out.

What was qualified

Two seasonal lane qualifications to ISTA 7D, a payload-specific pack-out specification, receipt and release criteria for each site, and a documentation set that tied every claim to a test, a lane and a revision.

Outcome

Lanes cleared qualification inside ten weeks and the audit closed with no cold-chain findings. The transport section went into the filing referencing the study records rather than carrier promises.

02Autologous cell therapy · European depot network

Cryogenic product, and a depot that could not prove custody.

Problem

A cell therapy sponsor added two depots to a vein-to-vein chain that had never been audited at that handoff. Dry shipper requalification intervals were undocumented, receipt steps were verbal, and a single excursion had already been closed on assumption rather than evidence.

What was qualified

Dry shipper qualification and requalification schedule, a written receipt and re-freeze procedure, an excursion decision tree with hold and release criteria, and a GDP audit of both depots with a corrective action plan.

Outcome

Both depots were approved and the custody trail now stands on signed records. Shipments since have moved without a temperature excursion and the decision tree has been used twice to release product with evidence rather than goodwill.

Client names withheld; details are described with permission. Outcomes above are drawn from the qualification records of the engagements shown.

Discuss a similar lane
04Twenty years · Five responses

3 pandemics. 2 disasters. 1 answer.

2009
H1N1
FEMA response
2014
Ebola
UNICEF & FEMA
2017
Hurricane Maria
Puerto Rico
2019
COVID-19
Johnson & Johnson
2021
Hurricane Ida
New Orleans
Not once did we fail. Because the person at the end of the cold chain was waiting for something they could not live without.
Field incident archive: five responses, all passed
Field incident archive · five unplanned events · all tests passed
05Independence

We do not sell packaging. We do not take referral fees.

A validation strategy written by a party with a commercial interest in the equipment under assessment invites an avoidable question during inspection. Independence removes the question entirely.

01No financial vendor relationships

No ownership, affiliation, referral arrangement or revenue relationship with any shipper manufacturer, packaging supplier, courier, 3PL or depot operator in your network.

02No mark-up on testing

Laboratory costs are quoted to you directly and carry no mark-up, so the volume of testing we specify is never a revenue lever for us.

03Evidence assessed on merit

Vendor qualification data is assessed on its merits and escalated where it falls short, without us sitting on both sides of that assessment.

04The framework is portable

Change shipper, pack-out or 3PL before launch and the qualification framework survives it, rather than needing to be rebuilt around a new vendor.

06Who leads your work

Carli Derifield, Founder & SME Consultant

Carli Derifield
Founder & SME Consultant · Newport Beach, CA

Twenty years across cold chain, quality and regulatory, on the buy side and the build side. Third cold chain company, after building and exiting two packaging companies.

First to own and operate an ISTA-certified thermal testing laboratory. Funded and authored the first ISTA Standards 20, 14 and 7E. Expert author on the Pharma.Aero PQI paper on supplier qualification.

Called in for H1N1, Ebola, Hurricane Maria, COVID-19 and Hurricane Ida.

2024
MIT Leadership & Innovation
2022
Inc. 5000 Honoree · No. 2,950
2011
First ISTA-certified thermal laboratory
—
ISTA Standards 20, 14 and 7E author
The leader you actually get

The person who writes your strategy is the person who executes it, answers the agency's questions about it, and is in the building for the inspection. No account manager. No hand-off to a junior team after the sale.

07Our partners

A team of 60+ independent SMEs. One contract.

Cold Chain Consult

Strategy · Validation · Regulatory

Transportation validation strategy, BLA content and IR responses, lane qualification, thermal test design, ICH Q9(R1) risk review, network optimization.

4 experts · California

TEN-E

Laboratory Testing

Thermal and cold chain (ISTA 7D, 7E), insulated shipper validation, distribution and hazard testing, dangerous goods. ISO/IEC 17025 accredited.

58 experts · MN · NC · CA

Two privately owned and operated firms. Roughly 60 subject matter experts, one team, one contract: a single vendor approval instead of two, and no investor-backed parent setting the methods.

08We have guided · twenty years

Trusted from start-up biotech to global pharma.

Client logo wall including Johnson & Johnson, Pfizer, Amgen, Genentech, AstraZeneca, Eli Lilly and Bayer

Sponsors, CDMOs, couriers, depots and standards bodies, and, as often as not, both sides of the same lane. And more.

In their words

What clients say afterwards.

“We came in with a validation package nobody trusted. Sixty days later we had a defensible lane strategy and a filing that cleared without an information request.”
VP, Global Supply Chain
Top-five biopharma
“The study design was something our carrier could actually execute, and it held up in the audit. No consultant has moved that fast on our program.”
Director, Quality & Distribution
Medical device manufacturer
“Two weeks from first call to shipment release during a national shortage. She knew which lane would hold and which would fail before we loaded a pallet.”
Head of Logistics
National health system

Attributions withheld at client request · we have guided 30+ organizations

Cold Chain Consult

When it cannot fail.

Tell us where the cold chain is uncertain and we will tell you what it would take to make it defensible: strategy, evidence and the answer at the filing.

Direct
Carli Derifield
carli@coldchainconsult.com
+1 714 262 6955
Office
2901 W Coast Hwy
Newport Beach, CA 92663
Web
coldchainconsult.com
Newport Beach · Global
Start a conversation

#20YearsInTheCold · Empowering Cold Chainge

INC. 5000 #2,950 — 2022EU GDP GUIDELINES 2013/C 343/01FDA 21 CFR PART 211.142WHO GOOD DISTRIBUTION PRACTICESISTA 7D THERMAL PACKAGE TESTINGISTA 7E THERMAL SHIPPER QUALIFICATIONAUTHOR — ISTA STANDARDS 20, 14 & 7EPACKAGING QUALIFICATION & VALIDATIONSHIPPING-LANE QUALIFICATION & THERMAL MAPPING2°C–8°C PHARMACEUTICAL COLD CHAIN−20°C FROZEN & DRY ICE SHIPMENTSCRYOGENIC CGT & PERSONALIZED MEDICINE15°C–25°C CONTROLLED ROOM TEMPERATURECLINICAL TRIAL MATERIAL LOGISTICS20+ YEARS IN THE COLD CHAININC. 5000 #2,950 — 2022EU GDP GUIDELINES 2013/C 343/01FDA 21 CFR PART 211.142WHO GOOD DISTRIBUTION PRACTICESISTA 7D THERMAL PACKAGE TESTINGISTA 7E THERMAL SHIPPER QUALIFICATIONAUTHOR — ISTA STANDARDS 20, 14 & 7EPACKAGING QUALIFICATION & VALIDATIONSHIPPING-LANE QUALIFICATION & THERMAL MAPPING2°C–8°C PHARMACEUTICAL COLD CHAIN−20°C FROZEN & DRY ICE SHIPMENTSCRYOGENIC CGT & PERSONALIZED MEDICINE15°C–25°C CONTROLLED ROOM TEMPERATURECLINICAL TRIAL MATERIAL LOGISTICS20+ YEARS IN THE COLD CHAIN
Cold Chain Consult — Your Missing Link

Founded by Carli Derifield. Independent pharmaceutical cold-chain consulting: shipping-lane qualification, packaging and thermal validation. Newport Beach, California.

INC. 5000 HONOREE 2022
MIT LEADERSHIP & INNOVATION · 2024
ACCEPTING NEW CLIENTS
CONTACT
© 2026 Cold Chain Consult · Carli Derifield. All rights reserved.
Privacy policyInc. 5000 #2,950 · 2022